Nanobiotix shares jump 6.3% after response data for treatment-resistant melanoma
Key Facts
Nanobiotix shares rose 6.3% on Monday after the company reported data from a clinical study of treatment for advanced cutaneous melanoma resistant to anti-PD-1 therapy, according to Investing.com. In a statement issued on October 24, 2026, the company said it had announced final data from the Phase 1 study evaluating JNJ-1900, also known as NBTXR3, with immune checkpoint inhibitors. The study included 24 patients and recorded an overall response rate of 41.7%, or 10 patients. Responses included four complete responses, while the disease control rate was 75%, or 18 patients. The results remain preliminary because they came from a single-arm study, and researchers said they warrant further evaluation in randomized trials.
Median progression-free survival was 6.9 months, while median overall survival reached 17.8 months, according to company data. The study recorded responses in injected lesions, at a rate of 45.8% among 24 evaluable patients. Responses also appeared in non-injected lesions, at a rate of 30.0% among 10 evaluable patients. These results describe responses at injected and non-injected tumor sites, alongside the survival measures reported by the company. But they do not by themselves establish the treatment's efficacy, as researchers said the approach needs to be tested in a larger randomized study.
All participants had advanced cutaneous melanoma resistant to anti-PD-1 treatment, and 14 were at stage IV. The statement described participants as having received extensive prior treatment and said most had undergone other immunotherapies before joining the study. Prior treatments included anti-CTLA-4 in 50% of patients, anti-LAG-3 in 33.3%, and T-VEC in 25%. Immunotherapy was the most recent treatment received before enrollment by 87.5% of participants. These characteristics put the response results in the context of a group previously treated with immunotherapy that had not responded to anti-PD-1 treatment.
Participants received one intratumoral injection of JNJ-1900 at the recommended Phase 2 dose, after which the injected lesion underwent stereotactic radiotherapy. Patients then received nivolumab or pembrolizumab, according to the company's description of the treatment design. The company said no new safety signals were observed and described the safety profile as acceptable. In an exploratory analysis of plasma samples from 8 patients, IL-1β recorded the largest increase from baseline among the cytokines assessed. The company presented this finding as an exploratory analysis within the study.
Researcher Jason Chan said patients whose disease progresses after anti-PD-1 treatment, often after other immunotherapies, face limited options. He added: "These are early data from a single-arm study, and they support testing the approach in a randomized trial." Investigators concluded that the preliminary results warrant further evaluation in randomized trials involving patients with cutaneous melanoma who had not received or had not responded to anti-PD-1 treatment. Chan presented the data in a poster session on October 24, 2026, at the European Society for Medical Oncology annual meeting in Madrid. Janssen Pharmaceutica, a subsidiary of Johnson & Johnson, is developing the treatment under a licensing agreement signed in 2023.
In trading, NBTX closed at $29.36 on October 23, 2026, according to EL7 data. The closing price had been $21.08 on October 19 before reaching $29.36 on October 23. Investing.com reported Monday's 6.3% rise after the study data were released. The source linked the share move to the results announcement without attributing it to broader factors in the biotechnology sector. The next step identified by the researchers is to evaluate the approach in randomized trials.